Our very own David Adair will be representing Solas BioVentures at the NC Life Sciences Emerging Company and Technology Luncheon and Forum! Taking place on Thursday 2/27, this event will showcase leaders and emerging technologies that are pushing the boundaries in life sciences. Dr. Adair, with his deep expertise and passion for innovation, will be sharing insights into our mission to drive breakthroughs in healthcare and support pioneering ventures in the industry. ?? Learn more about the event here: https://lnkd.in/eXyhHh-F We're excited to be a part of this discussion and continue our work in advancing life-changing innovations. #LifeSciences #Innovation #Leadership #EmergingTechnologies #SolasBioVentures
Solas BioVentures
投资管理
Chattanooga,Tennessee 1,676 位关注者
Not your ordinary VC. We invest in Medtech & Biotech entrepreneurs bringing seismic improvements in patient outcomes.
关于我们
Solas BioVentures is a venture capital firm that invests in early and development stage biopharma, medical device, diagnostics, and digital health companies.
- 网站
-
https://solasbio.com
Solas BioVentures的外部链接
- 所属行业
- 投资管理
- 规模
- 2-10 人
- 总部
- Chattanooga,Tennessee
- 类型
- 私人持股
- 创立
- 2015
- 领域
- Medical Devices、Biotechnology和Venture Capital
地点
Solas BioVentures员工
-
Amy Grogg, PharmD
-
Dr. Michael Ackermann, PhD, MBA
Co-Founder, Board Member and Chief Business Officer at Arrivo BioVentures LLC
-
Lana B. Caron
Healthcare Innovation | Business Development | Venture Capital | Strategic Partnerships
-
Frank B.
Richard X. Zhang Endowed Professor of Business in the Gary W. Rollins College of Business
动态
-
Exciting news to share on my birthday! ?? Today, I’m celebrating not just another year, but also the incredible strides being made in healthcare innovation. Francis Medical has secured $80M to advance water vapor ablation technology for treating prostate, kidney, and bladder cancer. I couldn’t be more thrilled to see such innovation making waves in the industry. It’s moments like these that remind me why I’m passionate about working in this space—driving progress that changes lives. Feeling grateful for another year and for the opportunity to witness advancements like these. Here's to many more milestones in health and innovation! https://lnkd.in/eECgcSCB
-
Excited to be part of #LSTCON2024 in Nashville! With Isaiah Reeves, PhD (where we met just last year!). It's an incredible event bringing together industry leaders to drive innovation and celebrate breakthroughs in #pharma, #meddevice, #diagnostics, and more. This year, I’m honored to serve as a judge for the pitch competition, where we’ll spotlight some of the most promising innovations shaping the future of life sciences. Looking forward to connecting with peers, exchanging ideas, and championing groundbreaking solutions in the industry. Thank you to Life Science Tennessee for organizing such an impactful event and to the sponsors who make it possible. Let’s make this a memorable experience! #Innovation #LifeSciences #Leadership
-
-
The Digital Health Applications (DiGAs) framework is revolutionizing how digital health technologies are brought to market in Europe. But how is this evolving, and what does it mean for Healthtech companies looking to succeed in the European market? In our upcoming LSI Europe ‘24 panel, "The DiGAs Framework, and the Evolution of Getting Healthtech to Market in Europe," we’ll explore this framework in depth. Our panelists will discuss the opportunities and challenges presented by DiGAs, how the framework is shaping market entry strategies, and what this means for the future of Healthtech innovation in Europe. Featured Panelists: ? Samantha J. — Elaia Partners ? Martin Müller — CARMA FUND Management GmbH ? Laurent Pacheco, MD MBA PhD (Econ.) — Solas BioVentures ? Amine Benmoussa — Karista Join us at LSI Europe ‘24 this September 16-20th to see more panel sessions like this and connect with hundreds of global Medtech and Healthtech leaders in Sintra, Portugal. Apply on our website today while space is still available.
-
-
We are thrilled to share that our Managing Partner David Adair, will be participating in a panel at LSI Europe '24. He will be joined by our portfolio company CEO, Robert Krummen of Vektor Medical, Inc., along with esteemed co-investors Luc Marengere from TVM Capital Life Science, Ashley Seehusen from SANTé, and Alexander Goemans CFO at Xeltis. The discussion will focus on "Building Syndicates of Cross-Border Investors in Medtech Companies." Will you be attending? Let us know - we'd love to connect! #LSIEurope24 #LSIAlumni #Medtech #LifeSciences #MedicalTechnology #VentureCapital #HealthTech
-
-
Congrats to Francis Medical for treating their 100th patient!
?? Exciting Update! Yesterday, our 100th #VAPOR2 clinical trial patient was treated! Thank you to Dr Eric Giesler and his team at Urology Austin, and to all of our VAPOR 2 sites, for your partnership in evaluating #WaterVaporTherapy for treating #ProstateCancer! ?? Learn about #VAPOR2 #ClinicalTrial at https://lnkd.in/gt5UzREe L to R: Ariel Del Bosque (ForTec Medical, Inc.), Michael Hoey, Dr. Eric Giesler (Investigator, Urology Austin), Dr. Christopher Dixon, Jennifer Penshorn (Research Coordinator, Urology Austin), Rich Hill, Amanda Dover, MBA, BSN, RN, Walker Cunningham #ToughOnCancerGentleOnPatients
-
-
I'm looking forward to attending the biotech day summit with Kavya Sharman, PhD, Phase Capital, 615.vc, and many more amazing people in Nashville. More info at: https://lnkd.in/ev2VdTFf
-
-
As a provider of specialized care for women for over 30 years, I'm excited to see a novel mechanism that has the potential to impact millions struggling with depression. Did you know that depression affects roughly two-thirds of females worldwide? With Arrivo BioVentures LLC championing SP-642, we may soon have an answer for better depression care. As a clinician, nothing is scarier than the 6 inches between someone's ears. There are no obvious hemorrhages or lab tests to assist in depression diagnosis. Solas BioVentures has placed a marker on this one as we collectively believe it is going to be game-on for depression and possibly other targets in CNS. Platform plays such as this program help patients tremendously, as depression seldom exists in a vacuum. Well done team Arrivo and big congrats on the first patient enrollment. Today we celebrate the first patient dosed in the Phase 2B clinical trial for SP-642! Read more about the trial and our progress here: https://lnkd.in/eFktp3QD #Depression #WomensHealth #SP624 #SIRT6 #MentalHealth